Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Leucine-rich a-2 glycoprotein as a potential biomarker of idiopathic multicentric Castleman disease with pulmonary involvement: a single-center case-control study from Japan.
Takata S, Takeda Y, Hirata H, Shirai Y, Morita T, Futami Y, Naito Y, Masuhiro K, Shiroyama T, Miyake K, Naka T, Kumanogoh A. Takata S, et al. Among authors: masuhiro k. J Thorac Dis. 2022 May;14(5):1332-1341. doi: 10.21037/jtd-21-1973. J Thorac Dis. 2022. PMID: 35693615 Free PMC article.
Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study.
Shiroyama T, Tamiya M, Minami S, Takata S, Masuhiro K, Futami-Nishijima Y, Uenami T, Mori M, Koba T, Matsuki T, Takimoto T, Suzuki H, Okamoto N, Komuta K, Hirashima T, Kumanogoh A, Kijima T. Shiroyama T, et al. Among authors: masuhiro k. Cancer Chemother Pharmacol. 2017 Sep;80(3):461-467. doi: 10.1007/s00280-017-3385-7. Epub 2017 Jul 7. Cancer Chemother Pharmacol. 2017. PMID: 28688052 Clinical Trial.
Skin Rash Can Be a Useful Marker for Afatinib Efficacy.
Nasu S, Suzuki H, Shiroyama T, Tanaka A, Iwata K, Ryota N, Ueda Y, Takata SO, Masuhiro K, Morita S, Morishita N, Okamoto N, Hirashima T. Nasu S, et al. Among authors: masuhiro k. Anticancer Res. 2018 Mar;38(3):1783-1788. doi: 10.21873/anticanres.12416. Anticancer Res. 2018. PMID: 29491117
Transformation to small cell lung cancer after first-line afatinib treatment.
Shiroyama T, Nasu S, Tanaka A, Takata S, Masuhiro K, Takada H, Morita S, Morishita N, Suzuki H, Okamoto N, Kawahara K, Hirashima T. Shiroyama T, et al. Among authors: masuhiro k. Respir Med Case Rep. 2018 Mar 1;23:188-190. doi: 10.1016/j.rmcr.2018.02.011. eCollection 2018. Respir Med Case Rep. 2018. PMID: 29719814 Free PMC article.
Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study.
Shiroyama T, Nagatomo I, Koyama S, Hirata H, Nishida S, Miyake K, Fukushima K, Shirai Y, Mitsui Y, Takata S, Masuhiro K, Yaga M, Iwahori K, Takeda Y, Kida H, Kumanogoh A. Shiroyama T, et al. Among authors: masuhiro k. Sci Rep. 2019 Feb 21;9(1):2447. doi: 10.1038/s41598-019-39120-6. Sci Rep. 2019. PMID: 30792455 Free PMC article.
A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma.
Masuhiro K, Koh G, Takata S, Nasu S, Takada H, Morita S, Tanaka A, Shiroyama T, Morishita N, Suzuki H, Okamoto N, Kawasumi H, Konishi C, Hirashima T. Masuhiro K, et al. Respir Med Case Rep. 2019 May 26;28:100862. doi: 10.1016/j.rmcr.2019.100862. eCollection 2019. Respir Med Case Rep. 2019. PMID: 31194139 Free PMC article.
37 results